Washington D.C., Nov. 4, 2024 – Global Alzheimer’s Platform Foundation® (GAP) applauds Eisai and Biogen on the completion of the rolling submission of the application to the U.S. Food and Drug Administration (FDA) for the subcutaneous maintenance dosing of Leqembi. If approved, this autoinjector could greatly improve the patient experience, reducing the need for biweekly one-hour visits in a specialist’s office to a quick, 15-minute appointment at home or a local medical facility.
John Dwyer, President of the Global Alzheimer’s Platform Foundation stated, “We congratulate Eisai on this important milestone with the FDA. This can be a game changer for people who do not have easy access to traditional hospital systems. The availability of an alternative dosing option will make it easier for patients to access this disease-modifying medication. It is encouraging news to be one step closer to a process that will improve the lives of people living with Alzheimer’s disease, and we look forward to tracking the progress of this application.”
For immediate release:
Contact: media@globalalzplatform.org
About the Global Alzheimer’s Platform Foundation (GAP):
The nonprofit Global Alzheimer’s Platform Foundation was founded to speed the delivery of Alzheimer’s treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and duration of clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible.